FGC
TGTX icon

Financial Gravity Companies’s TG Therapeutics TGTX Stock Holding History

Financial Gravity Companies’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$0 Buy
+41
New +$204 ﹤0.01% 1514

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Financial Gravity Companies's TGTX Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in TG Therapeutics (TGTX) in Q4 2018: 41 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1514 among its holdings.

115 funds tracked by Wall St. Rank hold TGTX as of Q4 2018.

  • Financial Gravity Companies held 41 shares of TG Therapeutics worth $0 as of Q4 2018.
  • TG Therapeutics was a new Financial Gravity Companies position in Q4 2018.
  • TG Therapeutics made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #1514 holding.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.